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Abstract 
Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of 
the synovial joints. Early intervention followed by early diagnosis can result in disease remission; however, both early 
stage diagnosis and provision of effective treatment have been impeded by the heterogeneity of RA, which details of 
pathological mechanism are unclear. Regardless of numerous investigations of RA by means of genomic and prot-
eomic approaches, proteins interplaying in RA synovial tissues that contain various types of synoviocytes, are not yet 
sufficiently understood. Hence we have conducted an HPLC/mass spectrometry-based exploratory proteomic analy-
sis focusing on synoviocyte lesions laser-microdissected (LMD) from formalin-fixed paraffin-embedded (FFPE) synovial 
tissues (RA, n = 15; OA, n = 5), where those of Osteoarthritis (OA) were used as the control.
Results: A total of 508 proteins were identified from the RA and OA groups. With the semi-quantitative comparisons, 
the spectral index (SpI), log2 protein ratio (RSC) based on spectral counting, and statistical G-test, 98 proteins were 
found to be significant (pair-wise p < 0.05) to the RA synovial tissues. These include stromelysin-1 (MMP3), proteins 
S100-A8 and S100-A9, plastin-2, galectin-3, calreticulin, cathepsin Z, HLA-A, HLA-DRB1, ferritin, neutrophil defensin 1, 
CD14, MMP9 etc.
Conclusions: Our results confirmed the involvement of known RA biomarkers such as stromelysin-1 (MMP3) and 
proteins S100-A8 and S100-A9, and also that of leukocyte antigens such as HLA-DRB1. Network analyses of pro-
tein–protein interaction for those proteins significant to RA revealed a dominant participation of ribosome pathway 
(p = 5.91 × 10−45), and, interestingly, the associations of the p53 signaling (p = 2.34 × 10−5). An involvement of 
proteins including CD14, S100-A8/S100-A9 seems to suggest an activation of the NF-kB/MAPK signaling pathway. 
Our strategy of laser-microdissected FFPE-tissue proteomic analysis in Rheumatoid Arthritis thus demonstrated 
its technical feasibility in profiling proteins expressed in synovial tissues, which may play important roles in the RA 
pathogenesis.
Keywords: Rheumatoid arthritis, Osteoarthritis, Synovial tissues, Formalin-fixed paraffin embedded (FFPE), HPLC/
mass spectrometry, Spectral counting, Protein–protein interaction network analysis
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune 
disease characterized by chronic inflammation of the 
synovial joints, ultimately leading to joint cartilage 
destruction and permanent disability. It presents several 
systemic features as various organs are affected including 
skin, lungs, kidneys, blood vessels and the heart [1–4]. 
RA currently affects around 1 million people in Japan, [5] 
and approximately 1% of the population worldwide [6–
8]. This inflammatory disorder is initiated by self-attack 
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from one’s own immune system, but the details of the 
pathological mechanism are not clear. Recently, genomic 
and proteomic technologies have dramatically extended 
our ability to investigate the pathogenic process of RA. 
A series of reports has compared “fingerprint” profiles 
using a proteomic approach, which has found some RA-
specific proteins including S100A9/A8, serum amyloid 
A, galectin, and ubiquitin–proteasome pathway com-
ponents [9–26]. However, most of these studies were 
conducted with peripheral blood, synovial fluid (SF), or 
cultured synovial cells from patients with RA, when in 
fact most synoviocytes responsible for the inflammatory 
joint disorders in RA are found in the whole RA synovial 
tissue. Only a few studies have focused on the expression 
profile of such whole RA synovial tissue. Recent advance-
ments in shotgun sequencing and quantitative mass 
spectrometry for protein analyses could make proteom-
ics amenable to clinical biomarker discovery [27–30]. 
Moreover, selective collection of target cells from for-
malin fixed paraffin embedded (FFPE) tissues by laser 
microdissection (LMD) will allow access to tissues of 
a variety of cell types with a definite diagnosis. [31–34] 
Hence, we have applied this approach in order to attain a 
proteomic profile of RA from laser-microdissected FFPE 
synoviocyte lesions, which will help better understand 
the molecular mechanisms involved in RA.
Results and discussion
Proteins candidates characteristic to RA and OA
We have identified a total of 508 proteins from OA and 
RA samples, among which 165 proteins were unique 
to RA, 309 proteins in common, and only 35 unique to 
OA, as shown in Fig. 1a. These proteins were subjected 
to Protein ANalysis THrough Evolutionary Relation-
ships (PANTHER) Classification System version 9.0, 
[35] highlighting their biological processes. As Fig.  1b 
shows, large differences were found at the following bio-
logical processes of proteins characteristically expressed 
in the RA vs. OA pair: 3, localization (GO:0051179); 5, 
biological regulation (GO:0065007); 6, response to stim-
ulus (GO:0050896); 8, multicellular organismal process 
(GO:0032501); 9, biological adhesion (GO:0022610); 11, 
immune system process (GO:0002376). Differential pro-
tein expression analysis has been performed by using the 
spectral index (SpI), [36] the fold change of a expressed 
protein in the base 2 logarithmic scale (RSC) [37] which 
are based on spectral counting. G test was used for evalu-
ating differential protein expression in pair-wise, RA vs. 
OA [38].
A protein characteristic to either group was defined to 
satisfy p < 0.05 in pairwise G-test, and RSC > 1 or < −1, 
under which criterions 98 proteins were characteristic to 
RA and 71 proteins to OA among 508 identified proteins. 
The list of total 169 proteins is given in Additional file 1: 
Table S4, in which contained numerous RA biomarkers 
known previously, for example, stromelysin-1 (MMP3) 
and proteins S100-A8 and S100-A9, and so on. Table  1 
lists the 31 proteins expressed in RA and OA with the 
significance of p values <0.0001 in G test, and under RSC 
values >2 or <−2.
A co-expression of both fibromodulin (FMOD) and 
biglycan (PGS1) observed in OA-group seems consistent 
with the recent study that those ECM proteins were sug-
gested by using the genetic mouse model to be essential 
in regulating chondrogenesis and extracellular matrix 
turnover in temporomandibular joint (TMJ) osteoarthri-
tis [39]. It was also reported that asporin, (also known 
as periodontal ligament-associated protein 1 (PLAP1), a 
member of the family of small leucine-rich proteoglycan 
(SLRP) family), is expressed within the cartilage extracel-
lular matrix (ECM) and have a genetic association with 
osteoarthritis [40].
The proteins, S100-A8 and -A9 (also known as mye-
loid-related protein 8 and 14, and calgranulin A and B) 
a
35         309          165









1 2 3 4 5 6 7 8 9 10 11
OA
RA
1, cellular component organization or biogenesis (GO:0071840) ; 2, cellular process (GO:0009987); 3,
localization (GO:0051179); 4, apoptotic process (GO:0006915); 5, biological regulation (GO:0065007); 6,
response to stimulus (GO:0050896); 7, developmental process (GO:0032502); 8, multicellular organismal 
process (GO:0032501); 9, biological adhesion (GO:0022610); 10, metabolic process (GO:0008152); 11,
immune system process (GO:0002376)
Fig. 1 a The Venn diagram of 508 proteins identified from both OA 
and RA synovial lesions. The numbers of proteins detected with at 
least two peptides are indicated by numbers. b PANTHER gene ontol-
ogy (GO) analysis on the biological processes of proteins preferen-
tially expressed in OA and RA.
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Table 1 Representative 31 proteins with p values <0.0001 in  G test, and RSC values >2 or <−2, which means the fold 
change of a protein higher than 4 or lower than 0.25, in pairwise comparison between RA and OA
Protein entry 
namea




in which a protein was 
identified





OA (n = 5) RA (n = 15) OA-group RA-group





365 1 12 2 84 7.667E−08 0.777 2.904




432 2 12 4 87 1.929E−06 0.747 2.261
DEF1 DEFA1 Neutrophil 
defensin 1
94 0 11 0 78 4.879E−10 0.733 4.177
RL7A RPL7A 60S ribosomal 
protein L7a
266 0 10 0 37 2.032E−05 0.667 3.125
TPM3 TPM3 Tropomyosin 
alpha-3 chain
284 1 10 5 102 4.128E−07 0.626 2.237
S10A8 S100A8 Protein 
S100-A8
93 0 9 0 85 8.08E−11 0.600 4.299
VINC VCL Vinculin 1,134 1 9 3 70 1.372E−05 0.567 2.257
S10A9 S100A9 Protein 
S100-A9
114 0 8 0 109 1.732E−13 0.533 4.654
EZRI EZR Ezrin 586 0 8 0 69 4.951E−09 0.533 4.003
FRIH FTH1 Ferritin heavy 
chain
183 0 8 0 40 9.239E−06 0.533 3.234
K2C6A KRT6A Keratin, type II 
cytoskeletal 
6A
564 0 7 0 156 1.084E−18 0.467 5.168






189 0 6 0 43 4.21E−06 0.400 3.335
PERM MPO Myeloperoxi-
dase
745 0 5 0 65 1.39E−08 0.333 3.918





366 0 5 0 46 1.922E−06 0.333 3.430
K2C5 KRT5 Keratin, type II 
cytoskeletal 5
590 0 4 0 93 1.039E−11 0.267 4.427
TRFL LTF Lactotransferrin 710 0 3 0 98 2.886E−12 0.200 4.502
K1C14 KRT14 Keratin, type I 
cytoskeletal 
14
472 0 3 0 81 2.257E−10 0.200 4.231
ACTN1 ACTN1 Alpha-actinin-1 892 0 3 0 47 1.481E−06 0.200 3.460
K2C6C KRT6C Keratin, type II 
cytoskeletal 
6C
564 0 1 0 64 1.799E−08 0.067 3.896
POSTN POSTN Periostin 836 2 5 17 13 5.517E−05 −0.082 −2.170




472 1 0 6 0 6.486E−05 −0.200 −4.349
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identified from RA synovial tissues were previously 
reported as biomarker candidates in RA sera, plasmas 
and synovial fluids [41]. Other known RA biomarker 
candidates were also detected, including thioredoxin 
domain-containing protein 5 (TXND5) [42] and thiore-
doxin-dependent peroxide reductase, mitochondrial 
(PRDX3).
Network analysis of candidate proteins
Network analysis of significant proteins is helpful in 
understanding how these proteins interplay with other 
key proteins and pathways. This study utilized significant 
proteins (n  =  98) relevant in RA to develop a predic-
tive network model, which has the potential to be used 
for further biological investigation. This was done using 
Search Tool for the Retrieval of Interacting Genes/Pro-
teins (STRING) database, [43, 44] in which data were 
obtained from biological functions of local networks 
surrounding the protein candidates. The STRING net-
work of proteins differentially expressed in RA is shown 
in Fig. 2, where node proteins of potentially importance 
in RA are indicated by red circles. STRING network 
enrichment analyses suggested a preferable association 
of RA with hematopoietic system disease (DOID 74: 
p  =  3.53  ×  10−10) and immune system disease (DOID 
2914: p  =  5.28  ×  10−9). Enrichment analyses on the 
KEGG pathways indicated that RA was dominantly 
associated with ribosome (has03010: p = 5.91 × 10−45). 
Interestingly, such would indicate that RA may involve 
protein networks that interplay with both p53 signaling 
(has04115: p = 2.34 × 10−5) and leukocyte transendothe-
lial migration (has04670: p = 5.75 × 10−4).
Recent therapeutic interventions for RA have been 
targeting cytokines, such as TNF-a, IL-1 and IL-17, a 
regulating matrix degradation. Numerous studies using 
anti-TNF agents have shown to slow or prevent the pro-
gression of bone and cartilage damage in RA, which 
could be attributed to the suppression of osteoclasts 
in joint lesions. Besides that, it have been reported that 
the pathogenesis of bone erosions in RA relates to the 
osteoclast-mediated bone resorption that is regulated by 
RANKL, the RANK (receptor activator of nuclear factor 
(NF)-kB) ligand [45]. RANKL is expressed by a variety 
of cell types involved in RA, including T-cells and syn-
oviocytes. NF-kB is activated in the synovium of patients 
with RA [12, 46] and regulates genes including TNF-
a, IL-6, IL-8, inducible nitric oxidase synthase (iNOS) 
and cyclooxygenase-2 (COX-2), all of which contribute 
to inflammation. It should be noted that the mitogen-
activated protein (MAP) kinases are also regulators of 








in which a protein was 
identified





OA (n = 5) RA (n = 15) OA-group RA-group




1,158 1 0 6 0 6.486E−05 −0.200 −4.349
COFA1 COL15A1 Collagen 
alpha-1 (XV) 
chain
1,388 1 0 7 0 1.354E−05 −0.200 −4.535
MYH11 MYH11 Myosin-11 1,972 1 0 10 0 1.273E−07 −0.200 −4.983
HBG2 HBG2 Hemoglobin 
subunit 
gamma-2
147 1 0 25 0 1.278E−17 −0.200 −6.207
ASPN ASPN Asporin 380 2 2 24 12 1.693E−08 −0.222 −2.744
HBD HBD Hemoglobin 
subunit delta
147 4 5 245 216 9.342E−48 −0.269 −2.012
CO4A C4A Complement 
C4-A
1,744 2 1 13 4 3.329E−06 −0.290 −3.254
COCA1 COL12A1 Collagen 
alpha-1 (XII) 
chain
3,063 2 1 17 5 6.862E−08 −0.294 −3.359
COEA1 COL14A1 Collagen 
alpha-1 (XIV) 
chain
1,796 4 6 167 108 4.41E−43 −0.329 −2.449
FMOD FMOD Fibromodulin 376 2 0 8 0 2.845E−06 −0.400 −4.700
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cytokine and metalloproteinase production [47, 48]. 
AKT2, IL6, MAPK1 and TP53 are all associated with the 
drugs used in RA treatment. It is known that methotrex-
ate (MTX) causes single- and double-strand DNA breaks, 
which are associated with TP53 [49–51]. It is also known 
that the p53 pathway is affected by bucillamine (Buc), 
which is mainly used for pain-reduction purposes as part 
of RA treatment in Japan [52].
Several proteins identified as being specific to the RA-
group are those related to human leukocyte antigens, 
such as HLA class I histocompatibility antigens, Cw-12 
(HLA-C 1C12) and A-33 (HLA-A), and HLA class II his-
tocompatibility antigen, DRB1-4 βα (HLA-DRB1). It has 
been considered that genetic similarities between RA 
patients and specific human leukocyte antigen (HLA)-DR 
genes, [12, 53], which reside in the major histocompat-
ibility complex (MHC) and participate in antigen presen-
tation, are associated with RA. The protein 2B14 is of the 
DRB1-4 β chain corresponding to the third hypervariable 
region, in which the susceptibility epitope may also influ-
ence the severity of the disease, and by which the strong-
est genetic link is suggested between the MHC and RA 
[54].
S100-A8 and S100-A9 (calgranulins, MRP8 and MRP14) 
are prominently released by activated macrophages. 
Inflammatory mediators such as IL-1, tumor necrosis fac-
tor (TNF) α or interferon (IFN) γ stimulate macrophages 
to up-regulate and secrete S100A8/S100A9, which 
induces proinflammatory responses in leucocytes and 
endothelial cells [55, 56]. One of the RA-related proteins 
Fig. 2 STRING protein–protein interaction networks of 98 differentially expressed proteins in RA synoviocyte lesions. This interaction map shown in 
evidence view was generated using default setting in network depth of 50 interactions under medium confidence (0.4) and the criteria for linkage 
only including experiments, databases, and textmining. Node proteins of potentially importance in RA were indicated by red circles.
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identified in this study includes CD14 (monocyte differ-
entiation antigen), which is involved in Toll-like receptor 
signaling [57]. It has been reported that Toll-like receptor 
(TLR) 4 is the dominant receptor for S100A8 signaling, 
and that stimulation by S100A8/S100A9 leads to nuclear 
factor (NF)kB and MAP kinase (MAPK) signalling [58, 
59]. S100A8 and S100A9 and the heterodimer accumulate 
in inflammatory fluids, suggesting that those are involved 
in the pathogenesis of rheumatoid arthritis [60].
Conclusions
We have employed in this study an exploratory proteomic 
analysis of laser-microdissected FFPE-tissues to eluci-
date protein expression profiles at synoviocyte lesions 
obtained from RA and OA patients, in which the OA 
samples served as the control. To the best of our knowl-
edge, this is the first proteomic study that has used FFPE 
synovial tissues of both RA and OA. Among a total of 
508 proteins identified we have elucidated 98 and 71 sig-
nificant proteins (p < 0.05 and RSC > 1 or −1) expressed 
in RA and OA, respectively. Molecular mechanisms 
leading to RA development involve quite a complex and 
diverse protein network interactions and thus is not yet 
completely understood. Identification, quantification 
and functional characterization of proteins are essential 
in further understanding RA pathogenesis. Our results 
confirmed the involvement of known RA biomarkers 
such as stromelysin-1 (MMP3) and proteins S100-A8 
and S100-A9, and also that of leukocyte antigens such 
as HLA-DRB1. The STRING protein–protein network 
analysis on RA indicated the dominant participation of 
ribosome pathway, and, interestingly, highlighted the 
associations of both the p53 signaling and NFkB/MAPK 
signaling pathways. We have successfully identified sev-
eral proteins expressed in RA synovial tissues, which may 
play important roles in RA pathogenesis. These results 
will help provide additional information about the molec-
ular mechanisms of RA and improve diagnostic strate-
gies in the future. Thus laser-microdissected FFPE-tissue 
proteomic analysis has its position as a technically fea-
sible method in this area and further research including 
exploratory and validation studies in individual patients 
in larger populations across multiple locations should be 
carried out in the future.
Methods
Ethics approval
The study protocol conformed to the principles of the 
Declaration of Helsinki. All patients were provided with 
informed consent and the study protocol was approved 
by both the Niizashiki Central General Hospital ethics 
committee and Medical ProteoScope Co. Ltd. Ethical 
committee.
Patients’ characteristics
Synovial tissue samples were obtained from patients with 
RA (n = 15) and OA (n = 5) undergoing a variety of ortho-
pedic surgery (wrist joint, elbow joint, hip joint, knee joint) 
at the Niiza Shiki Central general hospital. All patients ful-
filled the American College of Rheumatology criteria for 
the diagnoses of RA and OA [61–63]. Table 2 summarizes 
patients’ characteristics and clinical information.
FFPE tissue sample preparation
The synovial samples were dissected from connective tis-
sues and immediately stored at −80°C until use. Synovial 
tissues were then surgically removed and fixed with a 
buffered formalin solution containing 10–15% methanol 
and were finally embedded by a conventional method. 
Paraffin blocks were cut into 4-μm sections for diagnosis 
and 10-μm sections for proteomics. The 10-μm sections 
were stained only with haematoxylin, and diagnosis made 
using the 4-μm sections stained with haematoxylin-eosin 
(HE) according to the WHO classification.
Laser capture and protein solubilization
Targeted synoviocyte lesions were identified on serial 
sections of synovial tissues stained with hematoxylin and 
eosin (HE). For proteomic analysis, a 10-μm thick sec-
tion prepared from the same tissue block was attached 
onto DIRECTOR®slides (OncoPlexDx, Rockville, MD, 
Table 2 Patients’ characteristics and clinical information
The values are mean ± SD unless otherwise indicated.
DAS disease activity score, CRP C-reactive protein, MMP-3 matrix 
metalloproteinase 3, MTX methotrexate.
RA (n = 15) OA (n = 5)
Age (years) 62.9 ± 10.3 66.2 ± 9.7
Gender, n (% female) 11 (73.3) 5 (100.0)
Disease duration (years) 11.7 ± 9.0 5.7 ± 5.6
Stage (I/II/III/IV) 1/1/11/2
Class (I/II/III/IV) 1/5/8/1
DAS28-CRP 3.5 ± 1.1
CRP(mg/dL) 2.4 ± 2.2
MMP-3 (ng/mL) 430.8 ± 531.5
MTX use, n (%) 9 (60.0)
MTX dose (mg/week) 4.1 ± 3.6
Oral steroid use, n (%) 7 (46.7)
Oral steroid dose (mg/day) 1.4 ± 1.7
Biologics use, n (%) 3 (20.0)
Sampling site
 Wrist joint, n 3 0
 Elbow joint, n 1 0
 Hip joint, n 1 4
 Knee joint, n 10 1
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USA), de-paraffinized twice with xylene for 5 min, rehy-
drated with graded ethanol solutions and distilled water, 
and stained by hematoxylin. Those slides were air-dried 
and subjected to laser microdissection with a Leica 
LMD6000 (Leica Micro-systems GmbH, Ernst-Leitz-
Strasse, Wetzlar, Germany). The DIRECTOR® slide is 
similar to a standard glass (uncharged) microscope slide, 
but has an energy transfer coating on one side of the 
slide. Tissue sections are mounted on top of the energy 
transfer coating, and when the slide is turned over, the 
tissue faces down under the microdissection system. 
Targeting cells or tissue areas of interest are carried 
out on computer display. The laser energy is converted 
to kinetic energy upon striking the coating, vaporizing 
it and instantly propelling selected tissue features into 
the collection tube. At least 30,000 cells (ca. 8.0  mm2) 
were collected directly into a 1.5-mL low-binding plastic 
tube. Proteins were extracted and digested with trypsin 
using Liquid Tissue® MS Protein Prep kits (OncoPlexDx, 
Rockville, MD, USA) according to the manufacturer’s 
protocol. Targeted lesions were laser-microdissected 
from FFPE synovial tissues as exemplified in Fig. 3.
Liquid chromatography-tandem mass spectrometry
We adopted a label-free semi-quantitation using spectral 
counting by liquid chromatography (LC)-tandem mass 
spectrometry (MS/MS) to a global proteomic analysis. 
The digested samples were analyzed in triplicates and 
orders randomized by LC–MS/MS using reversed-phase 
liquid chromatography (Paradigm MS4; Michrom Biore-
sources, USA) (RP-LC) interfaced with a LTQ-Orbitrap 
XL hybrid mass spectrometer (Thermo Fisher Scientific, 
Bremen, Germany) via a closed nano-electrospray device 
(ADVANCE Spray Source; AMR Inc. Japan) as described 
in details previously [64]. Briefly, the RP-LC system con-
sisted of a peptide Cap-Trap cartridge (0.3  ×  5.0  mm) 
and a capillary separation column (an L-column Micro 
of 0.1 × 150 mm packed with reverse phase L-C18 gels 
of 3 μm in diameter and 12-nm pore size, (CERI, Tokyo, 
Japan)). An autosampler (HTC-PAL, CTC Analytics, 
Switzerland) loaded an aliquot of samples onto the trap, 
which was then washed with solvent A (98% distilled 
water with 2% acetonitrile and 0.1% formic acid) for con-
centrating peptides on the trap and desalting. The trap 







Osteoarthritis                          Rheumatoid Arthritis
Fig. 3 Examples of the laser microdissections (LMDs) of targeted lesions from a OA and b RA synovial tissues (1, before; 2, after) on the DIRECTOR® 
slides. The DIRECTOR® slide is similar to a standard glass (uncharged) microscope slide, but has an energy transfer coating on one side of the slide. 
Tissue sections are mounted on top of the energy transfer coating, and when the slide is turned over, the tissue faces down under the microdis-
section system. Targeting cells or tissue areas of interest is carried out on computer display. The laser energy is converted to kinetic energy upon 
striking the coating, vaporizing it and instantly propelling selected tissue features into the collection tube.
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column, and the whole columns were developed for 
100  min with a linear acetonitrile concentration gradi-
ent made from 5 to 35% solvent B (10% distilled water 
and 90% acetonitrile containing 0.1% formic acid) at 
the flow-rate of 300 nL/min. A 5 μL (corresponding to 
1/10 of total sample amount) was used for each LC–MS 
analysis.
An LTQ was operated in the data-dependent MS/MS 
mode to automatically acquire up to three successive MS/
MS scans in the centroid mode. The three most intense 
precursor ions for these MS/MS scans could be selected 
from a high-resolution MS spectrum (a survey scan) that 
an Orbitrap previously acquired during a predefined 
short time window in the profile mode at the resolution 
of 30,000 and the lock mass of m/z 536.1,654 in the m/z 
range of 350–1,500. The sets of acquired high-resolution 
MS and MS/MS spectra for peptides were converted 
to single data files and they were merged into Mascot 
generic format files for database searching.
Database search
Mascot software (version 2.2.06, Matrix Science, Lon-
don, UK) was used for database search against Homo 
sapiens entries in the UniProtKB/Swiss-Prot database 
(release 2012_02, 20413 entries). Peptide mass toler-
ance was 5  ppm, fragment mass tolerance 0.5  Da, and 
up to two missed cleavages were allowed for errors in 
trypsin specificity. Carbamidomethylation of cysteines 
was taken as fixed modifications, and methionine oxi-
dation and formylation of lysine, arginine and N-ter-
minal amino acids as variable modifications. A p values 
of  <  0.05 was considered significant, lists of identified 
proteins were made under the criterions, peptide prob-
ability >95%, protein probability >99% and 2 minimum 
unique peptides, and then were merged into a master file 
where the primary accession numbers and entry names 
from UniProtKB were used. The false positive rates for 
protein identification were estimated using a decoy 
database created by reversing the protein sequences in 
the original database; the estimated false positive rate of 
peptide matches was 0.2% under protein score threshold 
conditions (p < 0.001).
Semi-quantitative group-comparison with spectral 
counting
Mascot search results were processed through Scaffold 
software (version 3.3.3, Proteome Software, Portland, 
OR, USA) to semi-quantitatively analyze differential 
expression levels of proteins by the spectral counting as 
described [32]. The number of peptide MS/MS spectra 
with high confidence (Mascot ion score, p < 0.005) was 
used for calculating spectral counts. Differential pro-
tein expression analysis was performed by the spectral 
index, SpI, which takes into account non-normal dis-
tribution and limited replicates and/or sample sizes 
[36]. SpI takes a value between −1 to 1, and a protein 
of SpI  >  0.4 or <−0.4 are considered to be significant. 
RSC > 1 or <−1 corresponds to their fold changes >2 or 
<0.5. G test was used for evaluating differential protein 
expression in pair-wise cancer groups [38]. Although 
G test does not require replicates, spectral counts for 
each protein from triplicates were pooled and used for 
G-statistic calculation using a two-way contingency 
table arranged in two rows for a target protein and any 
other proteins, and two columns for cancer groups on 
an Excel macro. Statistical significance of p < 0.05 was 
used. The Yates correction for continuity was applied 
to the 2 × 2 tables. The spectral counts were calculated 
for identified proteins, and those from triplicate experi-
ments were pooled, thereby improving the performance 
of G-test and decreasing false positive rates significantly 
[38].
The correction has made handling of data containing 
small spectral counts, including zero, possible. Statisti-
cians, however, showed that the results of G-test using 
a contingency table containing small counts are not so 
convincing due to the assumption that the G statistic 
asymptotically obey a χ2 distribution with one degree 
of freedom. To validate the G-test results, we calculated 
exact p values for the significant proteins without mak-
ing any assumptions of statistical distribution, based on 
the permutational distribution of the test statistic, i.e., 
Fisher’s exact test and Mann–Whitney U test for the con-
tingency tables using a R package.
Network analysis of protein–protein interactions
Network analysis of protein–protein interactions was 
carried out by using STRING version 9.1, [43] in which 
nodes are proteins and edges are the predicted functional 
associations based on primary databases comprising of 
KEGG and GO, and primary literature. STRING predicts 
these interactions based on neighbourhood, gene fusion 
products, homology and similarity of coexpression pat-
terning. Network interaction scores for each node are 
expressed as a joint probability derived from curated 
databases of experimental information, text mining and 
computationally predicted by genetic proximity [44]. In 
this study, STRING networks were calculated with the 
default settings—medium confidence score: 0.400, net-
work depth: 0 and up to 50 interactions.
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